Targeting the oxidative activation of PKG Ialpha as a treatment for HFpEF

靶向 PKG Ialpha 的氧化激活作为 HFpEF 的治疗方法

• 批准号: MR/W023784/1
• 负责人: Philip Eaton
• 金额: $ 68.89万
• 依托单位: Queen Mary University of London
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=MR%2FW023784%2F1
• 关键词: Targeting; oxidative; activation; PKG; Ialpha

Heart failure is a common medical condition that causes the deaths of 200,000 people a year in the United Kingdom. Heart failure can be broadly categorised into two different type, and one them is called Heart Failure with Preserved Ejection fraction or HFpEF. The heart is a pump, filling with blood and then pumping it out to the rest of the body by contracting. This happens every time every time the heart beats. The problem for people with HFpEF is that their heart does not relax and fill with blood properly, not only directly impairing its ability to pump efficiently, but also causing triggering other changes in the heart tissue that make the situation progressively worse. We have identified an early stage drug that shows promise in the treatment of HFpEF, but we require more funds to enable work developing and evaluating this compound and derivatives we are making before studies in humans are possible. We think our studies are important as there are no drugs at this time that are effective in the treatment of HFpEF patients and unfortunately, this condition continues to become more prevalent.

心力衰竭是一种常见的疾病，在英国每年导致 20 万人死亡。心力衰竭大致可分为两种不同类型，其中一种称为射血分数保留的心力衰竭或 HFpEF。心脏是一个泵，充满血液，然后通过收缩将其泵送到身体的其他部位。每次心脏跳动时都会发生这种情况。 HFpEF 患者面临的问题是，他们的心脏无法正常放松和充满血液，不仅直接损害其有效泵血的能力，而且还会引发心脏组织的其他变化，使情况逐渐恶化。我们已经发现了一种早期药物，在治疗 HFpEF 方面显示出希望，但在人类研究成为可能之前，我们需要更多的资金来开发和评估我们正在制造的这种化合物和衍生物。我们认为我们的研究很重要，因为目前没有药物可以有效治疗 HFpEF 患者，不幸的是，这种情况继续变得更加普遍。